# Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries

> **NCT01061151** · PHASE3 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 3747 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** Zidovudine (ZDV)
- **DRUG:** Nevirapine (NVP): Antepartum Mothers
- **DRUG:** Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV]) tail
- **DRUG:** Lamivudine-Zidovudine (3TC-ZDV)
- **DRUG:** Lopinavir-ritonavir (LPV-RTV)
- **DRUG:** Emtricitabine-tenofovir disoproxil fumarate (Truvada [TRV])
- **DRUG:** Nevirapine (NVP): Infant short-course
- **DRUG:** Nevirapine (NVP): Infant extended
- **OTHER:** No Intervention
- **OTHER:** Discontinue triple ARVs
- **OTHER:** Continue triple ARVs

## Key facts

- **NCT ID:** NCT01061151
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-03-01
- **Primary completion:** 2016-09-30
- **Final completion:** 2016-09-30
- **Target enrollment:** 3747 (ACTUAL)
- **Last updated:** 2022-02-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01061151

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01061151, "Evaluating Strategies to Reduce Mother-to-Child Transmission of HIV Infection in Resource-Limited Countries". Retrieved via AI Analytics 2026-06-26 from https://api.ai-analytics.org/clinical/NCT01061151. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*